• Je něco špatně v tomto záznamu ?

Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapy

P. Vodárek, D. Écsiová, V. Řezáčová, O. Souček, M. Šimkovič, D. Vokurková, D. Belada, P. Žák, L. Smolej

. 2024 ; 13 (15) : e7399. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019441

Grantová podpora
League Against Cancer Prague
MH CZ - DRO UHHK 00179906 Ministry of Health, Czech Republic
Charles University in Prague

INTRODUCTION: The impact of chemoimmunotherapy (CIT) on immunoglobulin (Ig) quantities in patients with chronic lymphocytic leukemia (CLL) has not been extensively studied. METHODS: We analyzed Ig levels in 45 stable patients with indolent CLL (without indication for treatment) and 87 patients with progressive disease before first-line treatment. Fifty-five patients were evaluated again after the treatment with CIT. RESULTS: We observed significantly lower levels of all Ig classes and subclasses in patients with progressive disease compared to patients with indolent disease. After treatment, median IgA increased from 0.59 g/L to 0.74 g/L (p = 0.0031). In stable patients, lower IgA2 was associated with shorter time to first treatment, although it did not reach statistical significance (p = 0.056). Shorter overall survival was observed in patients with progressive disease and lower IgG2 (p = 0.043). Surprisingly, among the patients with progressive CLL, unmutated IGHV genes were associated with higher levels of IgG, IgG1 and IgM, while TP53 mutation and/or 17p deletion were associated with higher levels of IgA and IgA1. CONCLUSIONS: CIT may lead to increase in IgA levels. Hypogammaglobulinemia is more common in patients with progressive CLL and unmutated IGHV or TP53 dysfunction.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019441
003      
CZ-PrNML
005      
20241024110729.0
007      
ta
008      
241015s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.7399 $2 doi
035    __
$a (PubMed)39119792
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vodárek, Pavel $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000280507594 $7 xx0262638
245    10
$a Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapy / $c P. Vodárek, D. Écsiová, V. Řezáčová, O. Souček, M. Šimkovič, D. Vokurková, D. Belada, P. Žák, L. Smolej
520    9_
$a INTRODUCTION: The impact of chemoimmunotherapy (CIT) on immunoglobulin (Ig) quantities in patients with chronic lymphocytic leukemia (CLL) has not been extensively studied. METHODS: We analyzed Ig levels in 45 stable patients with indolent CLL (without indication for treatment) and 87 patients with progressive disease before first-line treatment. Fifty-five patients were evaluated again after the treatment with CIT. RESULTS: We observed significantly lower levels of all Ig classes and subclasses in patients with progressive disease compared to patients with indolent disease. After treatment, median IgA increased from 0.59 g/L to 0.74 g/L (p = 0.0031). In stable patients, lower IgA2 was associated with shorter time to first treatment, although it did not reach statistical significance (p = 0.056). Shorter overall survival was observed in patients with progressive disease and lower IgG2 (p = 0.043). Surprisingly, among the patients with progressive CLL, unmutated IGHV genes were associated with higher levels of IgG, IgG1 and IgM, while TP53 mutation and/or 17p deletion were associated with higher levels of IgA and IgA1. CONCLUSIONS: CIT may lead to increase in IgA levels. Hypogammaglobulinemia is more common in patients with progressive CLL and unmutated IGHV or TP53 dysfunction.
650    _2
$a lidé $7 D006801
650    12
$a chronická lymfatická leukemie $x farmakoterapie $x krev $x imunologie $x mortalita $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    12
$a imunoglobulin A $x krev $7 D007070
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a dospělí $7 D000328
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a progrese nemoci $7 D018450
655    _2
$a časopisecké články $7 D016428
700    1_
$a Écsiová, Dominika $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000268978756
700    1_
$a Řezáčová, Vladimíra $u Institute of Clinical Immunology and Allergology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000158021371
700    1_
$a Souček, Ondřej $u Institute of Clinical Immunology and Allergology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000331374200
700    1_
$a Šimkovič, Martin $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000303315334 $7 xx0117538
700    1_
$a Vokurková, Doris $u Institute of Clinical Immunology and Allergology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000169792825
700    1_
$a Belada, David $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000249816188 $7 mzk2006322730
700    1_
$a Žák, Pavel $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000344655343
700    1_
$a Smolej, Lukáš $u 4th Department of Internal Medicine-Hematology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic $u Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic $1 https://orcid.org/0000000241878595 $7 xx0101489
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 13, č. 15 (2024), s. e7399
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39119792 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110723 $b ABA008
999    __
$a ok $b bmc $g 2201965 $s 1231414
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 13 $c 15 $d e7399 $e - $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
GRA    __
$p League Against Cancer Prague
GRA    __
$a MH CZ - DRO UHHK 00179906 $p Ministry of Health, Czech Republic
GRA    __
$p Charles University in Prague
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace